Skip to main content

Table 4 Change in mean PRO measures from baseline to week 24 and follow-up visitsa

From: Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis

  Time point from baseline of the ATLAS study
PRO measure Week 24 Week 36 Week 52 Week 76 Week 104 Week 128 Week 156
BASDAI        
   n 288 278 274 270 262 242 236
   Mean ± SD change -3.1 ± 2.42 -3.4 ± 2.41 -3.5 ± 2.55 -3.8 ± 2.33 -3.9 ± 2.44 -3.9 ± 2.39 -3.9 ± 3.39
BASFI        
   n 288 b 274 270 261 242 236
   Mean ± SD change -2.2 ± 1.91 b -2.6 ± 2.04 -2.8 ± 2.10 -2.9 ± 2.14 -2.9 ± 2.17 -3.0 ± 2.10
SF-36 PCS        
   n 284 b 265 263 255 229 227
   Mean ± SD change 8.2 ± 9.01 b 10.19 ± 9.50 10.8 ± 9.88 11.0 ± 9.88 11.3 ± 9.68 11.6 ± 9.65
SF-36 MCS        
   n 284 b 265 263 255 229 227
   Mean ± SD change 4.8 ± 10.27 b 5.6 ± 10.35 5.1 ± 11.06 5.7 ± 10.96 4.1 ± 10.84 5.6 ± 11.59
SF-36 Physical Function        
   n 287 b 273 268 261 241 235
   Mean ± SD change 15.6 ± 20.99 b 19.5 ± 21.38 21.8 ± 21.79 21.9 ± 22.26 22.2 ± 22.34 23.3 ± 21.94
SF-36 Role–Physical        
   n 288 b 272 270 263 237 232
   Mean ± SD change 30.3 ± 40.48 b 37.2 ± 40.81 35.2 ± 40.72 39.1 ± 41.75 36.1 ± 42.39 37.8 ± 43.90
SF-36 Bodily Pain        
   n 288 b 274 270 263 237 233
   Mean ± SD change 24.0 ± 21.78 b 29.0 ± 22.96 29.7 ± 23.24 29.9 ± 23.74 31.8 ± 24.42 31.7 ± 24.33
SF-36 General Health        
   n 287 b 270 266 260 237 234
   Mean ± SD change 8.7 ± 17.37 b 11.3 ± 18.68 12.7 ± 19.25 12.5 ± 19.92 12.0 ± 18.84 12.7 ± 18.71
SF-36 Vitality        
   n 288 b 274 268 263 242 236
   Mean ± SD change 16.3 ± 19.82 b 19.5 ± 19.96 20.1 ± 19.65 20.4 ± 20.05 18.4 ± 19.85 20.1 ± 19.70
SF-36 Social Function        
   n 288 b 274 270 263 242 236
   Mean ± SD change 16.1 ± 23.88 b 19.7 ± 24.50 18.5 ± 23.73 20.6 ± 25.36 17.9 ± 26.01 22.3 ± 25.16
SF-36 Role–Emotional        
   n 286 b 271 268 260 235 230
   Mean ± SD change 17.2 ± 41.24 b 21.0 ± 44.40 19.5 ± 46.74 21.5 ± 46.01 16.9 ± 44.80 20.0 ± 46.06
SF-36 Mental Health        
   n 288 b 274 268 263 242 236
   Mean ± SD change 8.8 ± 16.52 b 10.1 ± 17.15 10.2 ± 17.50 10.6 ± 16.63 8.7 ± 16.96 10.5 ± 18.32
ASQOL        
   n 288 b 274 270 263 242 236
   Mean ± SD change -4.1 ± 4.23 b -4.8 ± 4.41 -5.0 ± 4.32 -5.4 ± 4.28 -5.3 ± 4.35 -5.4 ± 4.36
  1. aAll values P < 0.001 compared with baseline based on paired Student t-test.
  2. bMeasure not assessed at this time point.
  3. ASQOL = AS Quality of Life Questionnaire; ATLAS = Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS; BASDAI = Bath AS Disease Activity Index; BASFI = Bath AS Functional Index; MCS = Mental Component Summary; PCS = Physical Component Summary; PRO = patient-reported outcome; SD = standard deviation; SF-36 = Short Form-36 Health Survey.